Groups | PGI | PGII | PGR | G-17 |
---|---|---|---|---|
Control | 143.15±21.26 | 16.87±3.61 | 10.89±1.49 | 10.05±2.59 |
LGIN† | 187.21±25.73 | 18.95±3.96 | 12.33±2.82 | 14.26±3.47 |
HGIN† | 146.16±17.48 | 17.76±4.71 | 13.19±3.30 | 18.66±4.82 |
EGC† | 119.35±25.52 | 20.55±4.57 | 11.24±2.75 | 21.72±5.58 |
Advanced cancer | 94.85±28.72 | 17.3± 5.23 | 9.83±2.67 | 22.38±5.35 |
P-values | p<0.05* | p>0.05* | p>0.05* | p<0.05* |
p<0.05† | p>0.05† | p>0.05† | p<0.05† |
Values are presented as mean ± standard deviation (SD).
↵* comparison among all groups
↵† comparison among the LGIN, HGIN, and EGC groups.
PG: pepsinogen, PGR: PGI/PGII ratio, G-17: gastrin-17, LGIN: low-grade intraepithelial neoplasia, HGIN: high-grade intraepithelial neoplasia, EGC: early gastric cancer